Effects of hepatic artery chemoembolization using cisplatin-lipiodol suspension with gelatin sponge particles on swine liver.
OBJECTIVE
To define the effects of hepatic artery chemoembolization with cisplatin-lipiodol suspension and gelatin sponge particles on swine liver tissue and estimate the concentration of cisplatin that would have a minimal negative effect on normal liver parenchyma.


METHODS
Twelve pigs were divided into four groups: group A was the control group in which hepatic arteries were embolized with lipiodol and gelatin sponge particle (n = 3); group B animals were embolized with 10 mg/mL cisplatin-lipiodol suspension plus gelatin sponge particle (n = 3), group C with 20 mg/mL cisplatin-lipiodol suspension plus gelatin sponge particle (n = 3), and group D with 30 mg/mL cisplatin-lipiodol suspension plus gelatin sponge particle (n = 3). Pigs were euthanized 1 week after embolization, and the resected livers were cut into 10-mm-thick sections. The livers and necrotic foci were contoured in each section, and the necrosis volume ratio was calculated.


RESULTS
The necrosis volume ratios of the livers in groups A, B, C, and D were 0.832% +/- 0.334, 2.324% +/- 1.126, 8.056% +/- 3.276, and 11.82% +/- 4.921, respectively. Significant differences (P < .05) in necrosis volume ratio were found between groups A and C, groups A and D, groups B and C, and groups B and D; no significant difference was found between groups A and B.


CONCLUSIONS
Hepatic artery chemoembolization with higher doses of cisplatin causes greater damage to liver tissue; 10 mg/mL cisplatin-lipiodol suspension causes minimal damage, similar to that without cisplatin, and is related to minimal negative changes in a swine model.
Sahara
Shinya
S
Department of Radiology, Wakayama Medical University, Wakayamashi, Wakayama, Japan.
Tanihata
Hirohiko
H
Sato
Morio
M
Kawai
Nobuyuki
N
Takasaka
Isao
I
Minamiguchi
Hiroyuki
H
Nakai
Motoki
M
Sonomura
Tetsuo
T
D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects*; D002945:Cisplatin / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D006490:Hemostatics / Q000633:toxicity*; D007459:Iodized Oil / Q000633:toxicity*; D008099:Liver / Q000187:drug effects* / Q000473:pathology*; D013535:Suspensions / Q000633:toxicity; D013552:Swine
D000970:Antineoplastic Agents; D006490:Hemostatics; D013535:Suspensions; D007459:Iodized Oil; D002945:Cisplatin